HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HRA Pharma Sharpens Focus On OTC With Rare Diseases Split

Executive Summary

By shifting its rare diseases portfolio into a newly-created affiliate, HRA Pharma is signalling its intention to become a force in the global consumer healthcare market. 

You may also be interested in...

European OTC Results Round-Up: HRA Pharma, Boiron and Ipsen

HRA Pharma reports impressive sales growth in 2018, thanks largely to acquisitions. A drop in demand for homeopathic medicines hurts Boiron in Q1, while Ipsen enjoys a solid start to the year. 

HRA Pharma Breaks Into US Consumer Health Market With Mederma Acquisition

EllaOne and Compeed manufacturer HRA Pharma is set to establish a notable presence in the US consumer health market by acquiring the Mederma dermatology range from Germany's Merz.

HRA Pharma Reveals Big Growth Ambitions In Quest To Become Top-10 OTC Player

A combination of prescription-to-OTC switches, acquisitions and maximising the potential of its existing portfolio will take France’s HRA Pharma to the next level, reveals chief commercial officer Martyn Hilton. 

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts